학술논문
239. Efficacy and safety of 3 versus 6 months of low-dose valganciclovir for prevention of cytomegalovirus disease in moderate-risk (D+/R+ and D-/R+) renal transplant recipients receiving antilymphocyte antibody induction therapy.
Document Type
Academic Journal
Author
Source
Pharmacotherapy: The Journal Of Human Pharmacology And Drug Therapy. Oct 01, 2012 32(10):e248-e248
Subject
Language
English
ISSN
0277-0008